Pharvaris (NASDAQ:PHVS) Shares Down 4.3% - Should You Sell?

Pharvaris (NASDAQ:PHVS - Get Free Report) shares fell 4.3% on Tuesday . The stock traded as low as $14.50 and last traded at $15.02. 7,303 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 71,851 shares. The stock had previously closed at $15.70.

Analyst Ratings Changes

Separately, JMP Securities lifted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Trading Down 2.3 %

The firm has a market capitalization of $746.70 million, a P/E ratio of -5.10 and a beta of -2.84. The business has a 50 day moving average of $16.31 and a 200-day moving average of $18.72.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently made changes to their positions in PHVS. Jane Street Group LLC acquired a new position in Pharvaris in the 3rd quarter worth $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pharvaris in the third quarter valued at about $906,000. State Street Corp acquired a new position in shares of Pharvaris during the third quarter worth about $1,000,000. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock worth $685,000 after buying an additional 5,753 shares in the last quarter. Finally, Barclays PLC acquired a new stake in Pharvaris in the 3rd quarter valued at approximately $106,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.